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Background: Several studies in type 2 diabetes patients have shown significant associations between the SOD2
gene Val16Ala polymorphism and albuminuria, but this association has not been explored in the Mexican
population.
Methods: We evaluated the association between the SOD2 gene Val16Ala polymorphism (rs4880) and
macroalbuminuria in a sample of 994 unrelated Mexican type 2 diabetes patients. The study included 119 subjects
with urinary albumin >300 mg/dL and 875 subjects with urinary albumin ≤ 30 mg/dL. Genotyping of the SOD2
gene Val16Ala SNP was carried out with Real-Time Polymerase Chain Reaction (RT-PCR).
Results: The frequency of the TT genotype was 6.7% higher in participants with macroalbuminuria than in the
normoalbuminuria group (16.8% vs. 10.1%). Using a logistic regression analysis, we observed that individuals with
the CC genotype had significantly lower risks of macroalbuminuria than those with the TT genotype (OR=0.42,
p=0.034). We carried out a meta-analysis combining our data with data from four previous studies and estimated
an odds ratio (95% CI) for the C allele (with respect to the reference T allele) of 0.65 (0.52-0.80, p<0.001).
Conclusions: A significant association was found between the SOD2 Val16Ala polymorphism and
macroalbuminuria in a sample of Mexican type 2 diabetes patients.
Keywords: Mexicans, Macroalbuminuria, SOD2, Type 2 diabetes, Val16Ala polymorphismBackground
Diabetic nephropathy (DN) is the leading cause of chronic
kidney disease [1]. However, the risk factors for DN have
not been clearly established [2] and the pathogenesis of
the disease remains unclear. There is evidence indicating
that oxidative stress is associated with renal damage [3].
Macroalbuminuria is a predictor of DN, cardiovascular
morbidity and mortality [4-6].
Superoxide dismutase 2 (SOD2), also known as manga-
nese superoxide dismutase (MnSOD), is one of the major* Correspondence: mcruzl@yahoo.com
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distribution, and reproduction in any mediumantioxidant defense systems against mitochondrial super-
oxide radicals [7]. The Val16Ala non-synonymous poly-
morphism (rs4880) in the SOD2 gene has been predicted
to cause a conformational change in the target sequence,
from a partial alpha-helix in the Ala-variant (coded by the
C allele) to a beta-sheet in the Val-variant (coded by the T
allele), which induces a 30-40% decrease in SOD2 activity
due less efficient transport of the protein into the mito-
chondrial matrix [8,9].
Population differences in the incidence and progression
of renal diseases have been described previously [10,11].
Native Americans, Hispanics and Mexicans have higher
risk to develop DN in comparison with Europeans [12,13].
Contemporary Mexicans are an admixed population with
genetic background derived from indigenous Mexicand Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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recent study in Mexico City, the relative Native American
(NAM), European (EUR) and African (AFR) contributions
were estimated as 65, 30 and 5%, respectively [14].
Several studies in type 2 diabetes (T2D) patients of
Japanese, Korean and Chinese origin [15-18], as well as
a meta-analysis [19], have shown significant associations
between the SOD2 gene Val16Ala polymorphism and al-
buminuria, but this association has not been explored
in the Mexican population. The aim of the study was to
assess the association of the SOD2 gene Val16Ala poly-
morphism with macroalbuminuria in a sample of T2D
patients from Mexico City.
Methods
Ethics statement
The project was approved by the 3609 Local Ethics Com-
mittee of the National Institute of Social Security (IMSS)
according to the declaration of Helsinki. Written informed
consent was obtained from each participant.Study group
The study included 994 unrelated Mexican T2D pa-
tients recruited from primary care clinics of the IMSS,
in Mexico City, between 2008 and 2010. Diabetes diag-
nosis was done according to the American Diabetes
Association criteria, i.e. fasting plasma glucose ≥7.0
mmol/l or OGTT ≥11.1 mmol/l for the 2 h sample
[20]. Albuminuria was determined in spot urinary sam-
ples by nephelometric immunoassay. Participants with
macroalbiminuria (N=119) had urinary albumin >300
mg/dL, while normoalbuminuria (N=875) was defined
as urinary albumin ≤ 30 mg/dL [21]. None of the partic-
ipants showed any evidence of urinary tract infection,
hematuria, acute febrile illness, acute heart failure or vig-
orous exercise, based on clinical examination and general
urine testing. Data on age, gender, duration of T2D, body
mass index (BMI) and systolic and diastolic blood pres-
sure, previous diagnosis of hypertension, and hypertension
treatment with angiotensin converting enzyme (ACE) or
angiotensin receptor blockers (ARB) were also available
for each participant. We also measured fasting glucose,
glycated hemoglobin (Hb1Ac), LDL, HDL, and total chol-
esterol as well as triglycerides.DNA isolation
DNA was extracted from peripheral blood using the
QIAamp (Qiagen, Hilden, Germany) kit following the
manufacturer’s recommendations. DNA concentration
was measured by optical density (VICTOR3 1420 spectro-
photometer Perkin-Elmer, Massachusetts, USA), and in-
tegrity by electrophoresis in 0.8% agarose gels stained withethidium bromide (Gel Doc 2000, BIORAD, California,
USA).
SOD2 gene Val16Ala polymorphism (rs4880) genotyping
The SOD2 gene Val16Ala polymorphism was genotyped
with RT-PCR, using the TaqMan® SNP Genotyping Assay
(Applied Biosystems, California, USA).
Ancestry estimation
Individual admixture proportions were available for 386 out
of the 875 participants with normoalbuminuria, and for 53
of 119 subjects in the macroalbuminuria group. For these
individuals, Native American, European and West African
contributions were estimated with the program ADMIX-
TURE [22], using a genome-wide panel of approximately
37,000 Ancestry Informative Markers (AIMs). These 37,000
AIMs were present in both the Affymetrix Genome-Wide
Human SNP array 5.0 and the Axiom LAT Genome-Wide
Human Array (Affymetrix, Santa Clara, CA, USA), which
were used for high-density genotyping of the samples in an
unrelated study [23].
Statistical analysis
Differences between groups were assessed using t-Student
and chi-square tests for numerical and categorical vari-
ables, respectively. Deviations from the Hardy-Weinberg
proportions were evaluated using an exact test (available
at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
In order to test if the SOD2 gene Val16Ala polymorphism
was associated with macroalbuminuria, we used a logistic
regression model including as covariates sex, duration of
T2D, body mass index, systolic blood pressure, diastolic
blood pressure, current and previous smoking, HbA1c,
total cholesterol, HDL cholesterol, LDL cholesterol, previ-
ous diagnosis of hypertension and hypertension treatment
with ACE or ARB, which showed significant differences be-
tween groups in our preliminary univariate analyses. The
effect of the SOD2 gene Val16Ala polymorphism was tested
using an unconstrained genetic model, where the odds ra-
tios for the CC and CT genotypes were estimated inde-
pendently, using the TT homozygote, which has been
associated with lower SOD2 activity, as the reference geno-
type. In addition to the aforementioned analysis, we carried
out two additional logistic regression analyses: one for the
subset of the samples for which individual ancestry infor-
mation was available, and another using normoalbuminuric
subjects with more than 10 years of duration of T2D. The
goal of these additional analyses was to determine if
the association of the SOD2 gene Val16Ala polymorph-
ism with macroalbuminuria could be driven by popula-
tion stratification (e.g. differences in ancestry between
normoalbuminuria and macroalbuminuria groups) or
T2D duration. Finally, an inverse variance meta-analysis
including this study as well as previously published studies
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Demographic and biochemical characteristics of
study groups
A total of 119 participants with macroalbuminuria and 875
with normoalbuminuria were included in the study. Table 1
shows the clinical characteristics of participants by albu-
minuria group. With respect to the normoalbuminuric sub-
jects, the group of macroalbuminuric participants included
more males, had higher proportions of individuals diag-
nosed with hypertension and receiving hypertension treat-
ment, had longer duration of T2D, higher systolic and
diastolic blood pressure, higher HbA1c, higher total choles-
terol, HDL-cholesterol and LDL-cholesterol, lower body
mass index and a lower proportion of smokers. There were
no significant differences in age, fasting glucose, and triglyc-
erides between groups.
Association of the SOD2 gene Val16Ala polymorphism
with macroalbuminuria
Table 2 shows the allele and genotype frequencies of
the SOD2 gene Val16Ala polymorphism in the compari-
son groups. There were no significant deviations from
Hardy-Weinberg proportions in the normoalbuminuria
or macroalbuminuria groups. The frequency of the T al-
lele was higher in the macroalbuminuria group than in




Age (years) 58.2 ± 11.
Duration of T2D (years) 17.3 ± 9.8
Body mass index (kg/m2) 28.4 ± 4.6
Systolic blood pressure (mmHg) 136.9 ± 20
Diastolic blood pressure (mmHg) 85.8 ± 12.
Current or previous smoking/no smoking 38/81
Fasting glucose (mmol/L) 9.07 ± 4.4
HbA1c (%) 8.8 ± 3.4
Total cholesterol (mmol/L) 5.50 ± 1.8
HDL cholesterol (mmol/L) 1.14 ± 0.3
LDL cholesterol (mmol/L) 3.64 ± 1.4
Triglycerides (mmol/L) 2.67 ± 1.8
Previous diagnosis of hypertension yes/no 64/55
Hypertension treatment with ACE or ARB yes/ no 52/67
Data is shown as number (%) or average ± standard deviation. X2 test or t-Student
Angiotensin receptor blockers.respect to the genotypes, the frequency of the TT genotype
was 6.7% higher in the participants with macroalbuminuria
than in the normoalbuminuric subjects (16.8% vs. 10.1%).
The effect of the SOD2 gene Val16Ala polymorphism on
macroalbuminuria was evaluated using a logistic regression
model including sex, duration of T2D, body mass index,
systolic blood pressure, diastolic blood pressure, current
or previous smoking, HbA1c, total cholesterol, HDL-
cholesterol, LDL-cholesterol, previous diagnosis of
hypertension and hypertension treatment as covariates
(all these variables were significantly associated with
macroalbuminuria in our preliminary univariate ana-
lyses). Table 3 shows the OR estimates for all the vari-
ables showing significance in the logistic regression
analysis. Using an unconstrained genetic model, the
genotypes CT and CC had lower odds ratios for
macroalbuminuria than the reference TT genotype (CT:
OR 0.67, p=0.308; CC: OR=0.42, p=0.034). This analysis
did not include in the model individual ancestry propor-
tions, which was not available for all the participants.
Restricting our attention to the subset of the samples with
information on individual ancestry proportions, we ob-
served that macroalbuminuria subjects had a lower Native
American ancestry mean than normoalbuminuria group
(0.597 ± 0.027 vs. 0.663 ± 0.009, p=0.012) (Figure 1). The
odds ratios for the CT and CC genotypes in the logistic re-
gression analysis incorporating Native American ancestry
as a covariate were overly similar to those observed for the
full sample, although the p-values are weaker due to the
reduced sample size (CT: OR=0.59, p=0.400, CC:croalbuminuria
uminuria Normo albuminuria P
875 (88.0)
271/604 <0.001
2 57.2 ± 9.5 NS
7.2 ± 6.6 <0.001
29.4 ± 4.9 0.027
.2 125.7 ± 18.3 <0.001
1 78.8 ± 9.5 <0.001
418/457 0.001
3 8.8 ± 3.65 NS
7.48 ± 2.81 <0.001
6 5.12 ± 1.11 0.001
7 1.05 ± 0.36 0.015
3.15 ± 0.9 <0.001
9 2.43 ± 1.74 NS
353/522 0.005
245/630 <0.001
test P value. NS not significant, ACE Angiotensin Converting Enzyme, ARB
Table 2 Distribution of the SOD2 gene Val16Ala polymorphism among subjects
Allele Genotype
Gene Polymorphism Status T C TT CT CC PHW
SOD2 A16V Macroalbuminuria 99(41.6) 139(58.4) 20(16.8) 59(49.6) 40(33.6) 0.650
C>T Normoalbuminuria 576(32.9) 1174(67.1) 88(10.1) 400(45.7) 387(44.2) 0.320
PHW: Hardy-Weinberg equilibrium exact P value. Data is shown as number (%).
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for the CT and CC genotypes in the logistic regression
analysis using normoalbuminuria subjects with more than
10 years of duration of T2D was quite similar (CT: OR
0.45, p= 0.077; CC: OR=0.24, p=0.002).Meta-analysis with other available studies
We carried out an inverse variance meta-analysis includ-
ing our study and four additional studies for which geno-
type data are available. We report the results using an
allele model (C vs. T), but other models (e.g. codominant
or dominant TTvs. CC/CT) give consistent results. Table 4
reports the genotype and allele frequencies in the com-
parison groups, odds ratios and corresponding p-values
for each study. There was not evidence of significant het-
erogeneity between studies (Q=3.28, p=0.512), so we re-
port here the results of the fixed effects meta-analysis. A
forest plot with the estimates of odds ratios and 95% confi-
dence intervals (CI) for individual studies, as well as the
combined odds ratios and CI based on fixed effects and
random effects models, is shown in Figure 2. The results
of the meta-analysis are significant, with an odds ratio (CI)
of 0.65 (0.52-0.80, p<0.001) for the fixed effects model. A
sensitivity analysis excluding one study at a time indicates
that the results of the meta-analysis are quite robust, with
estimates of the odds ratios ranging from 0.52 to 0.80).Table 3 Results of the logistic regression analysis of the
SOD2 gene Val16Ala polymorphism and
macroalbuminuria
Variable OR (95%CI) P
Male sex 4.26 (2.41-7.53) <0.001
Duration of T2D (years) 1.14 (1.10-1.17) <0.001
Diastolic blood pressure (mmHg) 1.06 (1.03-1.09) <0.001
Current or previous smoking 0.41 (0.23-0.71) 0.002
HbA1c (%) 1.15 (1.05-1.25) 0.002
LDL cholesterol (mmol/L) 1.99 (1.29-3.10) 0.002
rs4880
CT genotype1 0.67 (0.31-1.45) NS
CC genotype1 0.42 (0.18-0.93) 0.034
Logistic regression analysis including sex, duration of T2D, body mass index,
systolic blood pressure, diastolic blood pressure, current and previous
smoking, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, previous
diagnosis of hypertension, hypertension treatment with ACE or ARB, and the
SOD2 gene Val16Ala polymorphism genotype. 1TT is the reference genotype.Discussion
Diabetic nephropathy is an important public health prob-
lem in Mexico. DN is the leading cause of end stage renal
disease in adults and is responsible for approximately 75%
of the total costs associated with the treatment of diabetic
complications [24]. Previous research has indicated that
there are population differences in the risk of developing
end stage renal disease, which is significantly higher in
African Americans, Asians and Latinos, relative to individ-
uals of European ancestry [10]. However, the ultimate rea-
sons for these prevalence differences have not been fully
elucidated. Many hypotheses have been proposed to ex-
plain the development of diabetes complications, includ-
ing DN. One of the hypotheses is that oxidative stress
plays a major role in the pathogenesis of diabetes compli-
cations [25]. For this reason, it is important to explore the
potential effect of polymorphisms located within the genes
coding for antioxidant enzymes, such as the SOD2 gene,
on DN risk. A number of studies have focused on the
SOD2 gene Val16Ala polymorphism, which is a non-
synonymous polymorphism that has been associated with
DN in several populations. However, although polymor-
phisms in the ACE [26] and TGF-β [27] genes have been
previously associated with DN in the Mexican population,
to our knowledge, the association between the SOD2 gene
Val16Ala polymorphism and macroalbuminuria has not
been yet studied in Mexico.
We genotyped the SOD2 gene Val16Ala polymorphism in
994 T2D patients: 119 individuals with macroalbuminuria
and 875 normoalbuminuric subjects. In a logistic regression
model incorporating other relevant covariates, the CT and
CC genotypes had lower odds ratios than the reference TT
genotype (CT: OR 0.67, p=0.308; CC: OR=0.42, p=0.034).
Given the different odd ratios observed for the CT and CC
genotypes, a codominant model (CC vs. CT vs. TT) seems
to provide the best fit to the data. Using a dominant model,
instead of an unconstrained model, the CC+CT genotypes
had an OR=0.55 (p=0.026), with respect to the TT genotype.
To our knowledge, ours is the largest study to date
evaluating the association of the SOD2 gene Val16Ala
polymorphism with macroalbuminuria. Our results are
consistent with a growing number of studies in different
population groups [15-19], and combining our study with
previously available data provides strong support for the
hypothesis that the SOD2 Val16Ala C allele, which codes
for the amino acid alanine, confers a protective effect
Figure 1 Triangle plot of individual admixture proportions. Triangle plot showing the distribution of the Native American (NAM), the
European (EUR) and the African (AFR) individual admixture proportions, in the normoalbuminuric and macroalbuinuric subjects.
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explained as a result of the conformational change caused
by alanine, which increases the efficiency of protein
targeting to the mitochondria, thereby leading to a rise of
reactive oxygen species scavenging in the mitochondria,
and a reduction in glomerular membrane damage due to
oxidative stress [8,9].
The contemporary Mexican population is the result of
an admixture process that involved Native American,
European and African populations. It is well known that
the presence of population stratification can inflate the
rate of false positives in association studies in admixed
populations [28]. For example, when there are substan-
tial differences in admixture proportions between cases
and controls, markers showing large frequency differ-
ences between the parental populations may be signifi-
cantly associated with the disease, even if they do notTable 4 Distribution of the SOD2 gene Val16Ala polymorphism
Genotype TT/CT/CC
Macroalbuminuria N
Authors (reference) Year Population Number PHW N
Nomiyama (15) 2003 Japan 74/14/0 1.000 20
Lee (16) 2006 Korean 36/4/1 0.178 20
Yang (17) 2007 Chinese 47/15/11 1.000 23
Liu (18) 2009 Chinese 55/7/0 1.000 78
Ascencio 2013 Mexican 20/59/40 1.000 88
All studies 232/99/52 <0.001 59
PHW Hardy-Weinberg equilibrium P value, OR odds ratio, CI confidence interval, P Pplay any causal role. One way to correct for the effects of
population stratification is to include individual admixture
estimates in the statistical models. Unfortunately, we do
not have ancestry estimates for all the individuals included
in this sample. However, this information is available for
approximately half of the sample, and this gave us the op-
portunity to explore if the inclusion of admixture esti-
mates in the model may alter the conclusions of our
study.
When we restricted our analysis to the participants for
which admixture information was available, we observed
that macroalbuminuria subjects had a lower Native
American ancestry than normoalbuminuria group (0.597 ±
0.027 vs. 0.663 ± 0.009, p=0.012). The odds ratios of the lo-
gistic regression analysis incorporating ancestry in the
model are similar to those observed in the full sample,
again indicating that the CC and CT genotypes have aamong groups, in albuminuria studies with T2D patients
C allele frequency
ormoalbuminuria
umber PHW Cases Controls OR (95%CI) P
6/83/2 0.038 8.0 14.9 0.49 (0.27-0.89) 0.017
3/24/17 <0.001 7.3 11.9 0.59 (0.24-1.40) 0.225
/25/2 0.183 25.3 29.0 0.83 (0.47-1.47) 0.525
/22/3 0.390 5.6 13.6 0.38 (0.16-0.90) 0.023
/400/387 0.320 58.4 63.7 0.69 (0.52-0.91) 0.008
8/554/411 <0.001 26.5 44.0 0.65 (0.52-0.80) <0.001
value between macroalbuminuric and normoalbuminuric subjects.
Figure 2 Forest plot of macroalbuminuria and SOD2 gene Val16Ala polymorphism. Forest plot of ORs for macroalbuminuria and SOD2
gene Val16Ala polymorphism in dominant model (CC+TC vs TT) in studies with T2D patients.
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p=0.400, CC: OR=0.31, p=0.081). The p-values obtained in
this analysis are slightly weaker than in the full sample, but
this is not surprising considering that the sample size was
reduced in half, with a subsequent reduction in power to
identify significant effects. Overall, our data suggests that
the significant results observed in the analysis of the full
dataset are not due to the presence of population stratifica-
tion. If stratification was responsible for the results ob-
served in the full sample, we would expect that an analysis
of the subsample incorporating ancestry in the statistical
models would lead to differences in the ORs observed in
both samples. Instead, the ORs are similar in both analyses
(in fact, the ORs for the CC and CT genotypes are slightly
lower in the model including ancestry than those observed
in the full sample, without correction for variation in
ancestral proportions). We also estimated the odds ratios
restricting the normoalbuminuric sample to subjects with
more than 10 years of duration of T2D and the results are
very similar to those observed in the full sample.
The allelic frequency of the SOD2 Val16Ala poly-
morphism risk allele T, which codes for the amino acid
valine, in the normoalbuminuric group from MexicoCity is quite similar to the frequencies observed in the
HapMap Mexican American sample from Los Angeles,
California (32.9% vs. 36.0%) (http://hapmap.ncbi.nlm.nih.
gov/cgi-perl/snp_details_phase3?name=rs4880&source=h
apmap28_B36&tmpl=snp_details_phase3). However, the
data available for other population groups indicate that
there is substantial dispersion of allele frequencies for this
polymorphism. For example, in populations from East
Asia the frequencies of the T allele are higher than 85%,
and in populations of African and European ancestry,
the T allele has intermediate frequencies, between 50%
and 65%.
In our logistic regression analyses, we included a num-
ber of covariates that were significantly associated with
macroalbuminuria in our sample (sex, duration of T2D,
body mass index, systolic blood pressure, diastolic blood
pressure, current or previous smoking, HbA1c, total chol-
esterol, HDL-cholesterol, LDL-cholesterol, previous diag-
nosis of hypertension and hypertension treatment). We
observed that adding the SOD2 Val16Ala polymorphism
to a model including the aforementioned factors increased
only slightly the goodness of fit of the model (McFadden's
pseudo R2 values increased from 0.361 to 0.369). Some of
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of T2D, diastolic blood pressure, HbA1c and LDL
cholesterol levels) have also been highlighted in previ-
ous studies [29,30]. However, in our sample we found
that current or previous smoking was inversely associ-
ated with macroalbuminuria. This stands in contrast to
other studies, in which smoking was found to be a risk
factor for DN [29-32], although other studies failed to
find associations of smoking and DN [33,34]. Unfortu-
nately, we only had information about current or pre-
vious tobacco use, and data were not available about
duration or intensity of smoking. Other limitations of
the study include the lack of information about other
microvascular complications such as retinopathy or
neuropathy, as well as for other factors that may be im-
portant in the pathogenesis of macroalbuminuria, such
as practice of regular physical activity, type of diabetes
medication, or variation in other enzymatic and non-
enzymatic antioxidants. Finally, it is important to note
that the sample of macroalbuminuria patients was rela-
tively small (119 individuals). This is related to the low
prevalence of macroalbuminuria among T2D patients.
For example, De Pablos et al. have reported that the
prevalence of macroalbuminuria among T2D patients
in a Spanish population was approximately 12% [35],
and in Mexico the prevalence has been estimated be-
tween 9 and 10% [36,37].
Conclusions
In summary, we show that the SOD2 gene Val16Ala poly-
morphism is associated with macroalbuminuria. Our re-
sults highlight the importance of exploring the effects of
polymorphisms located within genes relevant to oxidative
stress in order to understand the genetic basis of diabetes
complications.
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